The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Meta-analysis of the effects on safety of front-loading (FL), every-2-week (Q2W), and Q3W dosing of darbepoetin alfa (DA) in patients (pts) with chemotherapy-induced anemia (CIA).
John A. Glaspy
Consultant or Advisory Role - Amgen
Research Funding - Amgen
Dusan Kotasek
No relevant relationships to disclose
Jean-Luc Canon
Research Funding - GHDC
Dianne Tomita
Employment or Leadership Position - Amgen (B)
Stock Ownership - Amgen (B)
Helen Collins
Employment or Leadership Position - Amgen
Stock Ownership - Amgen
Lee Steven Schwartzberg
No relevant relationships to disclose